Skip to content
TriangleGet started
← Study library

NCT04576091 · REGISTRY CONDITION SEARCH

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-08-21

This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving BAY 1895344, stereotactic body radiation therapy in combination with pembrolizumab may shrink or stabilize head and neck squamous cell cancer for longer than treatment with radiation and immunotherapy without BAY 1895344.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum-tolerated Dose (MTD) (Escalation)

→

outcome · POSTED

Incidence of Dose Limiting Toxicities (DLT)

→

outcome · POSTED

Dose of BAY 1895344

→

outcome · POSTED

Incidence of Late Adverse Events

→

outcome · POSTED

Incidence of Adverse Events

→

outcome · POSTED

Locoregional Control

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

1-year Progression-free Survival

→

outcome · POSTED

2-year Progression-free Survival

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

1-year Overall Survival

→

outcome · POSTED

2-year Overall Survival

→

outcome · POSTED

Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score

→

outcome · POSTED

Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score

→

outcome · POSTED

Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score

→

outcome · POSTED

Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score

→

outcome · NOT POSTED

Potential Predictive Biomarkers of Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed recurrent or metachronous (second primary), unresectable head and neck squamous cell carcinoma, including oral cavity, oropharynx, larynx, hypopharynx, cutaneous, salivary gland, paranasal sinus, or cervical lymphadenopathy (head and neck cancer of unknown primary). Core needle biopsy (preferably at least three 18-gauge cores) or incisional biopsy is preferred over fine needle aspiration (FNA) for diagnosis of recurrent disease or new primary head and neck squamous cell carcinoma to provide sufficient tumor tissue for correlative studies. Unresectable refers both to patients who have declined surgery and patients deemed unresectable by otolaryngology. This includes patients for whom curative resection is medically contraindicated and/or would be associated with excessive surgical risk (as deemed by the consulting otolaryngologist) or undue surgical morbidity (e.g., total glossectomy, laryngectomy, and/or major resection requiring free flap reconstruction) * Patients must have either recurrent disease or a new primary squamous cell carcinoma of the head and neck within a previously irradiated area (radiotherapy to dose \>= 40 Gy, i.e., in-field recurrence) * Patients must have completed prior radiotherapy \>= 6 months prior to enrollment * Patients must meet at least one of the following criteria: 1) received prior platinum-containing chemotherapy; and/or 2) tumor expresses PD-L1 (Combined Positive Score \[CPS\] \>= 1) * Patients who have received anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy must have had disease progression while on this therapy. Patients who have not received prior anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy are also eligible * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 with pembrolizumab in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 50%) and a life expectancy of \>= 3 months * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment) * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (If total bilirubin \> 1.5 x ULN, direct bilirubin must be \< ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN (=\< 5 x ULN for patients with liver metastases) * Creatinine OR measured or calculated creatinine clearance (CrCl) \< 1.5 x institutional ULN OR glomerular filtration rate (GFR) \> 60 mL/min/1.73 m\^2 * CrCl should be calculated per institutional standard * Albumin \> 2.5 mg/dL * International normalized ratio (INR) or prothrombin time (PT) =\< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants * Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * Patients must have measurable disease (at least one measurable lesion) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Baseline imaging must include neck CT (preferably contrast-enhanced) and chest CT or skullbase to midthigh PET/CT (preferably with contrast-enhanced neck CT if diagnostic contrast-enhanced neck CT not available). Patients who have undergone surgery aside from biopsy may be included if gross disease is present within the surgical resection bed or at another site * Patients must have no contraindications to pembrolizumab, including no history of organ allograft transplantation or active autoimmune disease (active defined as having autoimmune disease-related symptoms and detectable autoantibodies) that has required systemic treatment in the past 2 years (i.e., use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Human immunodeficiency virus (HIV)-infected patients may participate IF they meet the following eligibility requirements: * They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective * They must have a CD4 count of greater than 250 cells/mcL * They must not be receiving prophylactic therapy for an opportunistic infection * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy (e.g., not hepatitis B surface antigen \[HBsAg\] reactive), if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load (e.g., HCV ribonucleic acid \[RNA\] \[qualitative\] is not detected) * Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial (e.g. basal cell carcinoma, early-stage differentiated thyroid carcinoma, low-risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer). Patients with 10 or fewer distant metastases may be eligible for this trial if they meet performance status inclusion criteria * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better * Enrolling site must perform PD-L1 testing on tumor biopsy per institutional protocol (local testing or tissue sent to outside laboratory for PD-L1 immunohistochemistry (IHC) 22C3 pharmDx). Combined positive score (CPS) is recommended for PD-L1 scoring. Test result does not need to be available at the time of enrollment and treatment initiation, unless the patient has not received prior platinum-containing chemotherapy. For patients without a history of platinum-containing chemotherapy, PD-L1 testing with CPS \>= 1 is required to be eligible to receive pembrolizumab * Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after completion of BAY 1895344 therapy or 4 months after completion of pembrolizumab therapy, whichever is later. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 therapy or 4 months after completion of pembrolizumab therapy, whichever is later * Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient * Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible Exclusion Criteria: * Patients who are unable to take oral medications * Patients with nasopharyngeal carcinoma, paranasal sinus cancers with histology other than squamous cell carcinoma, or salivary gland cancers with histology other than squamous cell carcinoma * Patients who have had more than one prior course of head and neck radiotherapy * Patients who have disease surrounding \>= 180 degrees of the carotid artery * Patients with gross tumor involvement of the mandible * Patients with widely metastatic disease. * Note: Patients with oligometastatic disease (defined as ten or fewer distant metastases) may qualify for the study * Patients who have had chemotherapy, targeted small-molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study * Note: Patients with =\< grade 2 neuropathy or =\< grade 2 alopecia are an exception to this criterion and may qualify for the study * Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * Patients who are currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment * Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\], or recombinant erythropoietin) within 4 weeks prior to initiating the study drug BAY 1895344 * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI) * Has had a prior monoclonal antibody other than anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =\< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier. Note: Patients who received anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy within 4 weeks prior to study initiation are eligible if they have exhibited disease expression while on this therapy * Has new or progressive brain metastases, or leptomeningeal disease * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, ductal carcinoma in situ of the breast, early-stage differentiated thyroid cancer, or low-risk prostate cancer. Note: As discussed above, patients with limited metastatic disease (10 or fewer distant metastases) may qualify for the study * Patients with carcinomatous meningitis should be excluded * History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1893544 or pembrolizumab * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis * Patients whose disease has improved or remained stable (no evidence of disease progression) while receiving therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent are ineligible * Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients with psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344, breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after the end of BAY 1895344 treatment. These potential risks may also apply to other agents used in this study * Has a known history of active tuberculosis (TB) * Has received a live vaccine within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. Similarly, coronavirus disease 2019 (COVID-19) vaccines are permitted
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or PET-CT scan and collection of blood samples throughout the trial.
    intervention Names
    1. Procedure: Biospecimen Collection
    2. Procedure: Computed Tomography
    3. Drug: Elimusertib
    4. Biological: Pembrolizumab
    5. Procedure: Positron Emission Tomography
    6. Other: Quality-of-Life Assessment
    7. Radiation: Stereotactic Body Radiation Therapy
    label
    Treatment (pembrolizumab, BAY 1895344, SBRT)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Undergo blood sample collection
    name
    Biospecimen Collection
    other Names
    1. Biological Sample Collection
    2. Biospecimen Collected
    3. Sample Collection
    4. Specimen Collection
    type
    PROCEDURE
  2. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Undergo CT and/or PET-CT scan
    name
    Computed Tomography
    other Names
    1. CAT
    2. CAT Scan
    3. Computed Axial Tomography
    4. Computerized Axial Tomography
    5. Computerized axial tomography (procedure)
    6. Computerized Tomography
    7. Computerized Tomography (CT) scan
    8. CT
    9. CT Scan
    10. Diagnostic CAT Scan
    11. Diagnostic CAT Scan Service Type
    12. tomography
    type
    PROCEDURE
  3. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Given PO
    name
    Elimusertib
    other Names
    1. ATR Inhibitor BAY1895344
    2. ATR Kinase Inhibitor BAY1895344
    3. BAY 1895344
    4. BAY-1895344
    5. BAY1895344
    type
    DRUG
  4. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Given IV
    name
    Pembrolizumab
    other Names
    1. BCD-201
    2. GME 751
    3. GME751
    4. Keytruda
    5. Lambrolizumab
    6. MK 3475
    7. MK-3475
    8. MK3475
    9. Pembrolizumab Biosimilar BCD-201
    10. Pembrolizumab Biosimilar GME751
    11. Pembrolizumab Biosimilar QL2107
    12. Pembrolizumab Biosimilar RPH-075
    type
    BIOLOGICAL
  5. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Undergo PET-CT scan
    name
    Positron Emission Tomography
    other Names
    1. Medical Imaging, Positron Emission Tomography
    2. PET
    3. PET Scan
    4. Positron emission tomography (procedure)
    5. Positron Emission Tomography Scan
    6. Positron-Emission Tomography
    7. PT
    type
    PROCEDURE
  6. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Ancillary studies
    name
    Quality-of-Life Assessment
    other Names
    1. Quality of Life Assessment
    type
    OTHER
  7. arm Group Labels
    1. Treatment (pembrolizumab, BAY 1895344, SBRT)
    description
    Undergo SBRT
    name
    Stereotactic Body Radiation Therapy
    other Names
    1. SABR
    2. SBRT
    3. Stereotactic Ablative Body Radiation Therapy
    type
    RADIATION
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
7
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Will investigate the association between potential predictive biomarkers of response to treatment. Tumor mutation burden will be categorized as high (above median) or low (equal to or below median). Other biomarker expression levels will be categorized as high versus absent/reduced. The chi-square or Fisher exact test will be used to study associations between expression levels and tumor response (complete response/partial response; stable/progressive disease). Associations with time-to-event endpoints will be investigated using the log rank test. Differences in change in circulating Ki67+ CD8+ T-cells relative to baseline between levels of tumor response will be explored using the t-test or non-parametric equivalent (e.g., Mann-Whitney) if appropriate. Cox regression will be used to explore associations between change in in circulating Ki67+ CD8+ T-cells and time-to-event endpoints. Other biomarkers will be analyzed similarly.
    measure
    Potential Predictive Biomarkers of Response
    time Frame
    Up to 2 years
primary Outcomes
  1. description
    Dose of elimusertib (BAY 1895344) and concurrent stereotactic (8 Gy x 3 RT) body radiation therapy. Two 3-week cycles of therapy.
    measure
    Maximum-tolerated Dose (MTD) (Escalation)
    time Frame
    Up to 6 weeks
  2. description
    Number of patients who experienced Dose Limiting Toxicities. DLTs are defined as occurrence of any of the following events, if judged by the Investigator to be possibly, probably or definitely related to study drug administration 1. Any Grade 4 or greater adverse event per the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5.0) observed within 90 days of the last dose of radiation therapy. 2. Grade 3 nonhematologic toxicity (not laboratory) lasting \>5 days despite optimal supportive care. 3. Any Grade 3 nonhematologic laboratory value if: • Medical intervention is required to treat the patient, or • The abnormality leads to hospitalization, or • The abnormality persists for \>1 week. 4. Febrile neutropenia. 5. Thrombocytopenia \<25000/mm3 if associated with bleeding requiring intervention. 6. Prolonged delay (\>2 weeks) in initiating Cycle 2 due to treatment-related toxicity.
    measure
    Incidence of Dose Limiting Toxicities (DLT)
    time Frame
    Within 90 days of treatment initiation
  3. description
    Dose of elimusertib (BAY 1895344) and concurrent stereotactic (8 Gy x 3 RT) body radiation therapy. Two 3-week cycles of therapy.
    measure
    Dose of BAY 1895344
    time Frame
    Up to 6 weeks
  4. description
    Number of patients that experienced Adverse Events and/or Serious Adverse Events assessed per Common Terminology Criteria for Adverse Events (CTCAE) version 5, at least possibly related to treatment.
    measure
    Incidence of Late Adverse Events
    time Frame
    After 90 days post discontinuation of treatment, up to 1 year
secondary Outcomes
  1. description
    Number of patients that experienced AEs and/or SAEs per CTCAE version 5 at least possibly related to treatment.
    measure
    Incidence of Adverse Events
    time Frame
    Up to 12 months
  2. description
    A competing risk analysis will be conducted with local failure, distal failure, and death as competing events. The cumulative incidence and 95% confidence interval for local failure will be estimated. Time to each event will be measured from the start of treatment regimen (day 1 pembrolizumab).
    measure
    Locoregional Control
    time Frame
    Up to 2 years
  3. description
    Number of patients experiencing Complete response or partial response per Response Evaluation Criteria in Solid Tumors 1.1 criteria. Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
    measure
    Overall Response Rate
    time Frame
    Up to 2 years
  4. description
    Median time from start of treatment regimen (day 1 pembrolizumab) until documented local or distal failure or death from any cause. Will be estimated using the method of Kaplan-Meier. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
    measure
    Progression-free Survival
    time Frame
    Up to 2 years
  5. description
    Percentage of patients alive without disease progression at 1 year. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
    measure
    1-year Progression-free Survival
    time Frame
    At 1 year
  6. description
    Percentage of patients alive without disease progression at 2 years. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
    measure
    2-year Progression-free Survival
    time Frame
    At 2 years
  7. description
    Median time from start of treatment regimen (day 1 pembrolizumab) until death from any cause. Will be estimated using the method of Kaplan-Meier.
    measure
    Overall Survival
    time Frame
    Up to 2 years
  8. description
    Percentage of patients alive at one-year post treatment.
    measure
    1-year Overall Survival
    time Frame
    Up to one year
  9. description
    Percentage of patients alive at two years post treatment.
    measure
    2-year Overall Survival
    time Frame
    Up to two years
  10. description
    The FACT-H\&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H\&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life.
    measure
    Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
    time Frame
    At Baseline prior to start of treatment
  11. description
    The FACT-H\&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H\&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life.
    measure
    Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
    time Frame
    At 3 months from start of treatment
  12. description
    The FACT-H\&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H\&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life.
    measure
    Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
    time Frame
    At 6 months from start of treatment
Full study description
brief Summary
This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving BAY 1895344, stereotactic body radiation therapy in combination with pembrolizumab may shrink or stabilize head and neck squamous cell cancer for longer than treatment with radiation and immunotherapy without BAY 1895344.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of BAY 1895344 with concurrent head and neck stereotactic body radiation therapy (SBRT) reirradiation and pembrolizumab. II. To determine the recommended phase 2 dose (RP2D) of BAY 1895344 in combination with concurrent head and neck SBRT and pembrolizumab. SECONDARY OBJECTIVE: I. To observe and record anti-tumor activity (overall response rate, progression-free survival, and overall survival) of BAY 1895344, SBRT, and pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC). EXPLORATORY OBJECTIVE: I. To identify predictive biomarkers of response to BAY 1895344, SBRT, and pembrolizumab, including, but not limited to the following: genetic alterations of ATM and other deoxyribonucleic acid (DNA) damage response genes, tumor mutational load, circulating tumor DNA, baseline tumor ATM mutation status, tumor PD-L1 expression, and change in circulating Ki67+ CD8+ T-cells relative to baseline. OUTLINE: This is a dose-escalation study of BAY 1895344 and stereotactic body radiation therapy (SBRT) given with fixed-dose pembrolizumab. Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 orally (PO) twice daily (BID) on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan and/or positron emission tomography (PET)-CT scan and collection of blood samples throughout the trial. After completion of study treatment, patients are followed up every 13 weeks for at least 24 months.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-aa16519313c78eebc546
      requested nct id
      NCT04576091
      primary nct id
      NCT04576091
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      d3625532f0ed2b66d02202943f57f381e0e62fc58e12769b26fcbc5f3b77da55
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-aa16519313c78eebc546
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04576091
      occurrences
      1. context exact
        NCT04576091
        end
        11
        exact text
        NCT04576091
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/82/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      19d43db50d02a225a12a866afcf04ab7af70de5e327a43cb1497671cd6c0455d
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d7fc53d05d286bb83010
      requested nct id
      NCT04576091
      primary nct id
      NCT04576091
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      payload sha256
      63003b482d6b182df1d8f5a1602bc3bb5a079e1e3380a1391883eec131ce7aca
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d7fc53d05d286bb83010
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04576091
      occurrences
      1. context exact
        NCT04576091
        end
        11
        exact text
        NCT04576091
        start
        0
      offset unit
      unicode_code_points
      query cond
      Salivary Gland Cancer
      query disease state id
      ds-salivary-gland-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      source json pointer
      /studies/48/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      19d43db50d02a225a12a866afcf04ab7af70de5e327a43cb1497671cd6c0455d
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e3fbf852d196bbf79de9
      requested nct id
      NCT04576091
      primary nct id
      NCT04576091
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      dbceddeb0a9aa1fca9d63cc03f8bf1f70368990978beed005fbf648602f06ece
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e3fbf852d196bbf79de9
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04576091
      occurrences
      1. context exact
        NCT04576091
        end
        11
        exact text
        NCT04576091
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/114/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      19d43db50d02a225a12a866afcf04ab7af70de5e327a43cb1497671cd6c0455d

    Preserved source evidence · Independent clinical review pending · Not medical advice